T. Rowe Price Associates
KYTX icon

T. Rowe Price Associates’s Kyverna Therapeutics KYTX Stock Holding History

T. Rowe Price Associates’s Portfolio KYTX Stock Details KYTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$13.4M Sell
1,555,287
-207,330
-12% -$1.73M ﹤0.01% 1144
2025
Q4 		$16.6M Buy
1,762,617
+250,418
+17% +$1.86M ﹤0.01% 1104
2025
Q3 		$9.07M Sell
1,512,199
-318,302
-17% -$1.27M ﹤0.01% 1251
2025
Q2 		$5.62M Buy
1,830,501
+1,250,897
+216% +$3.09M ﹤0.01% 1244
2025
Q1 		$1.12M Sell
579,604
-14,084
-2% -$41.6K ﹤0.01% 1897
2024
Q4 		$2.22M Sell
593,688
-34,534
-5% -$165K ﹤0.01% 1598
2024
Q3 		$3.07M Sell
628,222
-41,335
-6% -$319K ﹤0.01% 1446
2024
Q2 		$5.02M Sell
669,557
-260,077
-28% -$3.97M ﹤0.01% 1224
2024
Q1 		$23.1M Buy
+929,634
New +$25.9M ﹤0.01% 947

Other funds holding KYTX

GGI
GordonMD Global Investments Beverely Hills, California $144M AUM
GS
Gilead Sciences Foster City, California $2.12B AUM 143.53% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
IHG
Insight Holdings Group New York $1.42B AUM 41.03% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

T. Rowe Price Associates's KYTX Position: Q1 2026 in Review

T. Rowe Price Associates reduced its Kyverna Therapeutics (KYTX) stake by 12% in Q1 2026, selling an estimated $1.73M and leaving 1,555,287 shares worth $13.4M. The position accounts for ﹤0.01% of the portfolio, ranked #1144.

T. Rowe Price Associates first reported a position in KYTX in Q1 2024 and has held it in 9 quarters since. The position peaked at $23.1M in Q1 2024. 111 funds tracked by Wall St. Rank hold KYTX as of Q1 2026.

  • T. Rowe Price Associates held 1,555,287 shares of Kyverna Therapeutics worth $13.4M as of Q1 2026.
  • T. Rowe Price Associates sold 207,330 Kyverna Therapeutics shares in Q1 2026, an estimated $1.73M.
  • Kyverna Therapeutics made up ﹤0.01% of T. Rowe Price Associates's portfolio in Q1 2026, its #1144 holding.
  • T. Rowe Price Associates first reported a position in Kyverna Therapeutics in Q1 2024 and has held it in 9 quarters since.
  • T. Rowe Price Associates's Kyverna Therapeutics position peaked at $23.1M in Q1 2024.
  • 111 funds tracked by Wall St. Rank held Kyverna Therapeutics as of Q1 2026.

Based on T. Rowe Price Associates's 13F filing for Q1 2026, filed 15 May 2026.